These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31308625)

  • 1. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?
    Huang Y; Lin W; Chen Z; Wang Y; Huang Y; Tu S
    Drug Des Devel Ther; 2019; 13():2111-2125. PubMed ID: 31308625
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
    Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
    BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
    Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
    Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
    Mena-Vázquez N; Godoy-Navarrete FJ; Manrique-Arija S; Aguilar-Hurtado MC; Romero-Barco CM; Ureña-Garnica I; Espildora F; Añón-Oñate I; Pérez-Albaladejo L; Gomez-Cano C; Jimenez-Núñez FG; Padin-Martín MI; Fernández-Nebro A
    Clin Rheumatol; 2021 Jan; 40(1):133-142. PubMed ID: 32557255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
    Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
    Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
    Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
    Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21
    Wu EK; Henkes ZI; McGowan B; Bell RD; Velez MJ; Livingstone AM; Ritchlin CT; Schwarz EM; Rahimi H
    J Immunol; 2019 Dec; 203(11):2837-2849. PubMed ID: 31659014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
    Vicente-Rabaneda EF; Atienza-Mateo B; Blanco R; Cavagna L; Ancochea J; Castañeda S; González-Gay MÁ
    Autoimmun Rev; 2021 Jun; 20(6):102830. PubMed ID: 33887489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
    Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
    Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease.
    Horai Y; Miyamura T; Shimada K; Takahama S; Minami R; Yamamoto M; Suematsu E
    J Clin Pharm Ther; 2012 Feb; 37(1):117-21. PubMed ID: 21128990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
    Kiely P; Busby AD; Nikiphorou E; Sullivan K; Walsh DA; Creamer P; Dixey J; Young A
    BMJ Open; 2019 May; 9(5):e028466. PubMed ID: 31061059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
    Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
    Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
    Fernández-Díaz C; Loricera J; Castañeda S; López-Mejías R; Ojeda-García C; Olivé A; Rodríguez-Muguruza S; Carreira PE; Pérez-Sandoval T; Retuerto M; Cervantes-Pérez EC; Flores-Robles BJ; Hernández-Cruz B; Urruticoechea A; Maíz-Alonso O; Arboleya L; Bonilla G; Hernández-Rodríguez Í; Palma D; Delgado C; Expósito-Molinero R; Ruibal-Escribano A; Álvarez-Rodríguez B; Blanco-Madrigal J; Bernal JA; Vela-Casasempere P; Rodríguez-Gómez M; Fito C; Ortiz-Sanjuán F; Narváez J; Moreno M; López-Corbeto M; Mena-Vázquez N; Aguilera-Cros C; Romero-Yuste S; Ordóñez S; Villa-Blanco I; Gonzélez-Vela MC; Mora-Cuesta V; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2018 Aug; 48(1):22-27. PubMed ID: 29422324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical observation of rheumatoid arthritis associated interstitial lung disease patients and changes of serum cytokines thereof].
    Jian XD; Guo GR; Ruan YJ; Zhao B; Wang YC; Ning Q; Zhang YC
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1884-7. PubMed ID: 19039999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
    Mori S; Imamura F; Kiyofuji C; Sugimoto M
    Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management issues in rheumatoid arthritis-associated interstitial lung disease.
    England BR; Hershberger D
    Curr Opin Rheumatol; 2020 May; 32(3):255-263. PubMed ID: 32141954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.